Article info

Download PDFPDF

Original research
Antibody response to the COVID-19 ChAdOx1nCov-19 and BNT162b vaccines after temporary suspension of DMARD therapy in immune-mediated inflammatory disease (RESCUE)

Authors

  • Ai Phuong Tran School of Medicine and Pharmacology, The University of Western Australia, Perth, Western Australia, AustraliaDepartment of Rheumatology, St John of God Murdoch, Perth, Western Australia, Australia PubMed articlesGoogle scholar articles
  • Daniel Tassone Faculty of Medicine, Dentistry and Health Sciences, Melbourne Medical School, The University of Melbourne, Melbourne, Victoria, Australia PubMed articlesGoogle scholar articles
  • Johannes Nossent School of Medicine and Pharmacology, The University of Western Australia, Perth, Western Australia, AustraliaDepartment of Rheumatology, Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia PubMed articlesGoogle scholar articles
  • Nik Sheng Ding Faculty of Medicine, Dentistry and Health Sciences, Melbourne Medical School, The University of Melbourne, Melbourne, Victoria, AustraliaGastroenterology Department, St Vincent's Hospital Melbourne Pty Ltd, Fitzroy, Victoria, Australia PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Ai Phuong Tran; ai.tran{at}research.uwa.edu.au
View Full Text

Citation

Tran AP, Tassone D, Nossent J, et al
Antibody response to the COVID-19 ChAdOx1nCov-19 and BNT162b vaccines after temporary suspension of DMARD therapy in immune-mediated inflammatory disease (RESCUE)

Publication history

  • Received February 22, 2022
  • Accepted April 6, 2022
  • First published May 16, 2022.
Online issue publication 
May 16, 2022
  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.